Which diabetes drug wins? new study pits dapagliflozin vs empagliflozin
NCT ID NCT07311551
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two common diabetes drugs, dapagliflozin and empagliflozin, to see which works better for lowering blood sugar and weight in people with type 2 diabetes and a high body mass index. About 112 adults will take one of the two drugs for six months. Researchers will also check safety, liver and kidney function, blood pressure, and cost to help doctors choose the best option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.